- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sanofi, Hanmi Reach Deal on Novel Treatments in Diabetes
The deal is part of Sanofi's effort to recover ground in the diabetes market.
Sanofi and Hanmi Pharmaceuticals Co. Ltd today announced a $4.2 billion in which Sanofi will gain exclusive worldwide rights to develop and commercialize Hanmi’s novel diabetes treatments.
These include a long acting glucagon-like peptide-1 (GLP-1) receptor agonist, a weekly insulin and a GLP-1 and insulin that act in combination. Collectively, they are known as Hanmi’s Quantum project.
Hanmi, based in South Korea, will retain an option to commercialize its products in Korea and China.
The deal, announced jointly in Paris and Seoul, is seen as a way for Sanofi to revive its diabetes business to compete with Novo Nordisk and Eli Lilly, particularly in the area of long-acting therapies.
Hanmi’s efpegelenatide, a late-stage long acting GLP-1 RA, was featured at the 75th Scientific Sessions of the American Diabetes Association in June.
Pascale Witz
"The agreement to develop these three investigational diabetes medicines confirms Sanofi's long-term commitment to people with this disease," said , executive vice president, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure.
"We now have the opportunity to expand our existing portfolio by including medicines that are administered weekly as well as daily, which could extend our reach in basal insulin and expand our GLP-1-RA and GLP-RA/insulin combination prospects. In these ways, we aim to complement our current offerings and work to serve a broader patient population."
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
